濮阳东方医院男科治早泄评价好收费低(濮阳东方妇科好预约吗) (今日更新中)

SAN DIEGO (KGTV) — The Fourth of July is traditionally a fun-filled weekend for locals to enjoy delicious food and take in a fireworks show. And while the pandemic has put some limits on that, there are still ways to have fun safely.El Cajon and Poway are hosting fireworks displays and encouraging residents to practice social distancing by staying in their car or watching the show from a distance.The Del Mar Fairgrounds also continues to host delicious fair food weekends with Chicken Charlies, Roxy's, and many more delectable treats — all from the comfort of your car drive-thru style.Balboa Park is also reopening several museums with guidelines in place to keep visitors safe.(As a reminder, residents are encouraged to stay home if they feel ill and avoid large gatherings with people not from the same household. The county also requires residents to practice social distancing and wear a facial covering when within six feet of those not from the same household.)Balboa Park museum reopenings (Friday): Starting Friday, several Balboa Park museums will reopen with new sanitation and distancing guidelines in place. The Fleet Science Center, San Diego Natural History Museum, San Diego History Center, and more will welcome visitors back this weekend for months-long closures. More infoEl Cajon July 4 fireworks (Saturday): Locals in El Cajon will be able to catch fireworks over John F. Kennedy Park at 9 p.m. on July 4, though the park itself will be closed. The show will be visible over a wide area and city officials encourage residents to look up and enjoy the show from home safely. More infoPoway's July 4 fireworks (Saturday): Fireworks will launch from both Poway High School and Sportsplex in South Poway Business Park at 9 p.m. on July 4. The two locations will allow for a nearly 360-degree view of fireworks from the Sportsplex while allowing those who traditionally view the show near the high school to continue doing so. Tickets must be purchased to watch the show from Lake Poway's parking lot. More infoSan Diego County Fair food fun (Friday-Sunday): What's the July 4 weekend without some fair food? The Del Mar Fairgrounds is offering delicious bites from fair vendors Friday through Sunday from now until Sept. 7. Grab a bit from vendors like Chicken Charlies, Roxy's, Sugar Bear, and more! The fair is also hosting virtual exhibits showcasing student artwork, photography, and livestock shows. More info 2445

SAN DIEGO (KGTV) — The latest ABC News national polling average shows former Vice President Joe Biden leading President Donald Trump by 8 points.But a lot of people are wondering, can we trust the polls after what happened in 2016?The last time Donald Trump was on the ballot in 2016, the polls had him trailing former Secretary of State Hillary Clinton by an average of 3.2 percentage points, and we know what happened.However, pollsters weren’t off by as much as you might think.“At the national level, the polling was, remarkably, given all things, precise,” said Jay Leve, CEO of the polling firm SurveyUSA.Trump lost the popular vote by 2.1 points instead of 3.2, the most accurate these national polls had been in 80 years, according to an analysis by the American Association for Public Opinion Research.Where the polls did miss badly was at the state level, particularly in Pennsylvania, Michigan and Wisconsin, three states that were critical in the Electoral College.Leve said there were several reasons for the polling problems at the state level.“Polling is a very expensive undertaking and so it is not possible for the handful of media organizations with pockets deep enough to afford a public opinion poll to be able to poll in every critical battleground state,” he said.Another reason? “Some of it has to do with what’s called ‘weighting,’” he added.To understand weighting, you have to know the two R’s of a good poll: it needs to be representative and random.Random samples are critical to the accuracy of polling, and you can look to your kitchen for an example why. Picture adding salt to a soup. If you mix it right, you can check the taste with any one spoonful -- you don’t have to eat the entire pot. That’s because each spoonful is a truly random sample.If you don’t mix the salt in, you could easily wind up sampling a part of the soup without any salt.When you’re trying to sample the American public with a political poll, either over the phone or most of the time now online, it’s more challenging to get a perfectly random spoonful.“The challenge is to find the individuals in the right numbers and secure their cooperation. Those two things don’t automatically work in sync,” Leve said. “People don’t want to be disturbed. They want privacy and a pollster by definition is an interruption.”It turns out, certain people tend to resist taking polls, while others are more willing. Research shows people with college degrees are more likely to respond to surveys than high school grads.That means surveys run the risk of not being representative of the voter population at large, and Leve said that kind of imbalance played a big role in 2016.To make a sample representative, pollsters gather up as many responses as they can, then adjust them with a process called weighting -- basically boosting or shrinking responses from people with certain demographics to match census data and the expected turnout.“The weighting criteria that was in issue in 2016 was whether you had enough non-college educated white voters in your sample,” Leve said. “If you did, you got the Trump forecast correct.”State polls that didn’t weight by education level missed badly, because to an extent far greater than in previous elections, voters with a college education broke for Clinton while voters with a high school education backed Trump.There’s some evidence that pollsters have learned from their 2016 mistakes. Polling in the 2018 midterms was very accurate -- a full point better than the average over the last 20 years.So can we trust the polls this time around?Leve says yes, as long as you remember that polls are just a snapshot in time and Donald Trump is difficult to predict.“Don’t be surprised if something happens in the final four, five, six days of the election, right before November 3rd, that’s so unforeseeable that neither you nor I nor anyone watching us could have imagined. And if so, that’s going to throw all the polls off,” he said. 3979

SAN DIEGO (KGTV) — The back-to-back announcements of promising clinical trial results from Pfizer and Moderna may usher in a new era for vaccine technology.Both companies have candidates that rely on a new kind of vaccine strategy: RNA. Preliminary data show both candidates are more than 90 percent effective.On the surface, the vaccine candidates look like any other you’ve taken. They work by training your body to build up defensive weapons against a virus, like antibodies and T-cells.But instead of training your body by introducing a killed virus or a fragment of a virus, the vaccines from Moderna and Pfizer introduce a set of instructions called messenger RNA enclosed in a little blob of fat.“The key concept of RNA is that they’re messages, and they’re meant as short-term messages,” said Dr. Shane Crotty of the La Jolla Institute for Immunology.Crotty said there are 5,000 to 10,000 messages within a cell at any given time.Once administered, the mRNA in the vaccine instructs some of your cells to make the coronavirus’ signature spike protein. The spike protein on the surface of the coronavirus allows it to infiltrate and hijack cells.Even though the spike protein is just one of about 25 genes the virus has, preliminary results from the clinical trials suggest it is enough material to train the immune system without making the recipient sick.Crotty likened the process of training the immune system to spotting a sedan. If the coronavirus is a car, the spike protein might be the door.“There's no way that car door could turn into a whole car, but it's enough of a piece of a car for your immune system to recognize that car if it saw it again,” he said.Scientists started by sequencing the virus’ DNA from a sick patient, then encoding that genetic sequence into an mRNA instruction molecule that can be read by the manufacturing part of cells.From there, Dr. Crotty said it’s a bit like the messenger app Snapchat.The mRNA gets injected into the body, sending temporary instructions to your cells that last for a while, then disappear. mRNA does not genetically modify cells, he stressed.“They’re around as messages for some period of time and then they go away, and the cells get back to their normal job of reading their own messages instead of reading the messages you’re injecting in the vaccine,” he said.The concept has been around since the 1990s, but there are currently no RNA vaccines on the market for any pathogen, so Dr. Crotty said it’s hard to estimate how long their protective effects will last.Some vaccines offer a lifetime of protection, like the measles vaccine. Others offer decades of protection. The flu vaccine only lasts about six months.Dr. Crotty said the length of protection depends on how fast the virus mutates and how long the immune cells survive in the body.But even if the COVID-19 vaccine turns out to need an annual update, he’s optimistic. The best feature of RNA vaccines is that they can be quickly reprogrammed.Both Moderna and Pfizer are still in their Phase 3 trials, but they expect to finish them by December. Together, they estimate they’ll have enough doses for about 35 million people by the end of this year, primarily for healthcare workers and high-risk individuals. 3250

SAN DIEGO (KGTV) — The beloved founder of the popular Roberto's Taco Shop chain which began in San Diego died last week, according to the company.Dolores Robledo, 90, died on July 14, the company said in a release. Robledo opened the first Roberto's Taco Shop — and San Diego's first taco shop — with her husband, Roberto, in 1964, according to the company. Prior to that, the couple started their food career providing tortillas to stores and restaurants from their San Ysidro tortilla factory."Since then, Sra. Dolores had been sharing her love for family and authenticity through each meal served," the company said in a release. "She has left the legacy of her love and perseverance. The way she touched lives will remain ongoing. Dolores Robledo will be deeply missed. Please keep her family in your thoughts as they go through this difficult time."Robledo was the mother to 13 children and had 39 grandchildren, 50 great-grandchildren, and 5 great-great-grandchildren. In 1990, Roberto moved to Las Vegas and soon after decided to open his first taco shop in Las Vegas. With the help of her family, Roberto's expanded to 60 locations across California and Nevada.The Roberto's chain is believed to have started the variety of other eateries with the "berto's" suffix in San Diego. It's long-rumored that the famed California Burrito was created at one of these "berto's" shops, but which shop can claim that title continues to be debated.On Instagram, the company continued: "Sra. Dolores Robledo, founder of Roberto's Taco Shop, loved cooking good Mexican food for her family and friends. She and her family expressed that passion by opening their first Roberto's Taco Shop in San Diego in 1964. She will be missed but her legacy of cooking fine Mexican dishes will continue for generations to come."Visitation services for Robledo will be held at 4 p.m. on July 29 at Glen Abbey Memorial Park in Bonita. The services will be followed by a mass and committal service on July 30. Her full obituary can be found online. 2032

SAN DIEGO (KGTV) — The Department of Defense has awarded a San Diego biotech company up to million to help develop a next-generation drug to fight COVID-19.Sorrento Therapeutics calls the drug a “rapid countermeasure” against the disease, one that might serve as a vaccine substitute in certain populations or a critical stopgap tool if the virus mutates.“With this, we have a new platform potentially that can respond very quickly to any type of emerging threat,” said CEO Dr. Henry Ji.Sorrento is trying to become the first company to develop an approved DNA-encoded monoclonal antibody treatment. The approach is similar to the experimental monoclonal antibody treatment used on President Trump, but Sorrento’s concept is a more advanced version that offers several benefits.Sorrento’s drug is designed to be used as either a treatment in infected patients or a fast-forming layer of defense in healthy people. The company said its solution should be cheaper and easier to deploy than existing monoclonal antibodies, while offering vaccine-like protective effects that last for several months rather than just two or three weeks.Antibodies are one of the body’s key defense mechanisms. They seek out pathogens and bind to them, marking the invader for destruction like ground troops marking an enemy base for an airstrike. In some cases, antibodies can even neutralize an invader themselves by blocking its method of entry into cells.Monoclonal antibodies are antibodies designed by scientists to neutralize a pathogen. They are hand-picked, genetically modified super antibodies that are cloned in labs.However, the process of growing these super soldiers in the lab is difficult, transporting them requires a cold chain, and as a result, monoclonal antibodies are among the most expensive drugs in the world.Instead of giving people an infusion of pre-made antibodies, Sorrento’s idea is to give people a shot of DNA that instructs some of their cells to churn out perfectly pre-designed antibodies.“It's much easier to make enough DNA to treat a large number of people than it is to make enough protein to treat a large number of people. That’s just a fact about manufacturing,” said Dr. Robert Allen, Sorrento’s chief scientific officer on the project.Dr. Allen said the company is hopeful the drug will induce cells to make protective antibodies for six months or more.This DNA approach to an antibody treatment has never been approved for any disease but other companies are working on their own versions of it. Another biotech with ties to San Diego, Inovio Pharmaceuticals, became the first company to test this approach in humans in 2019 for a drug targeting the Zika virus.Sorrento’s approach is similar to the way DNA vaccines work, but it cuts out intermediary steps and jumpstarts the production of antibodies, rather than leaving the production of antibodies up to the body’s immune system. The result is that protective antibodies can start circulating in days after injection rather than weeks, the company said.“What this is capable of doing is it bypasses the need for the immune system,” said Dr. Mark Brunswick, Sorrento’s senior vice president for regulatory affairs.The drug is unlikely to replace a vaccine in most situations because vaccines can produce other defense mechanisms like T-cells that work in conjunction with antibodies. But the drug might work better than a vaccine for the elderly and others with weakened immune systems who are unable to produce a robust number of antibodies on their own, Brunswick said.Still, the company still has a lot of pre-clinical work and testing to go. Sorrento is hoping to have the drug ready for human trials in four to six months.By then, vaccines from Pfizer and Moderna will likely be widely available, but Dr. Ji said the world needs to prepare for the possibility this virus will mutate.“When you vaccinate hundreds of millions, potentially billions of people, the virus is under tremendous evolution pressure,” he said. “It will escape. It’s guaranteed that the virus is going to mutate and escape all of the vaccines we’re trying to create.”If it does, he said Sorrento will be ready to rapidly deploy its DNA-based countermeasure. 4223

来源：资阳报